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Purpose: To set up a framework combining robust treatment planning with adaptive reoptimization in order to
maintain high treatment quality, to respond to interfractional geometric variations and to identify those patients
who will benefit the most from an adaptive fractionation schedule.
Methods: The authors propose robust adaptive strategies based on stochastic minimax optimization for a series
of simulated treatments on a one-dimensional patient phantom. The plan applied during the first fractions should
be able to handle anticipated systematic and random errors. Information on the individual geometric variations
is gathered at each fraction. At scheduled fractions, the impact of the measured errors on the delivered dose
distribution is evaluated. For a patient having received a dose that does not satisfy specified plan quality criteria,
the plan is reoptimized based on these individually measured errors. The reoptimized plan is then applied during
subsequent fractions until a new scheduled adaptation becomes necessary. In this study, three different adaptive
strategies are introduced and investigated. (i) In the first adaptive strategy, the measured systematic and random
error scenarios and their assigned probabilities are updated to guide the robust reoptimization. (ii) In the second
strategy, the grade of conservativeness is adapted in response to the measured dose delivery errors. (iii) In the
third strategy, the uncertainty margins around the target are recalculated based on the measured errors. The
simulated treatments are subjected to systematic and random errors that are either similar to the anticipated
errors or unpredictably larger in order to critically evaluate the performance of these three adaptive strategies.
Results: According to the simulations, robustly optimized treatment plans provide sufficient treatment quality
for those treatment error scenarios similar to the anticipated error scenarios. Moreover, combining robust planning
with adaptation leads to improved organ at risk protection. In case of unpredictably larger treatment errors, the
first strategy in combination with at most weekly adaptation performs best at notably improving treatment
quality in terms of target coverage and OAR protection in comparison with a non-adaptive approach and the
other adaptive strategies.
Conclusion: The authors present a framework that provides robust plan reoptimization or margin adaptation of a
treatment plan in response to interfractional geometric errors throughout the fractionated treatment. According
to the simulations, these robust adaptive treatment strategies are able to identify candidates for an adaptive
treatment, thus giving the opportunity to provide individualized plans, and improve their treatment quality
through adaptation. The simulated robust adaptive framework is a guide for further development of optimally
controlled robust adaptive therapy models.
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2I. Introduction
Adaptive radiation therapy (ART) is an approach that allows for adaptation during the course of treatment to
patient-specific anatomical and/or biological changes that could not have been accounted for during the planning
process. By combining state-of-the-art medical imaging and treatment plan optimization to precisely deliver the
optimized dose plan to the patient, highly individualized radiation therapy for cancer patients can become a reality.
Treatment plan optimization software is supposed to respond to geometric variations in order to mitigate deviations
of the delivered dose from the intended dose distribution.
The robust approach to radiation therapy planning includes uncertainties in the treatment delivery process. Un-
certainties are caused for example by internal organ motion, geometric changes in the patient’s anatomy and setup
errors, which can be included in the optimization problem in different ways. The framework presented in this work
considers interfractional geometric variations only. Probabilistic methods optimize the expectation value of the ob-
jective function by incorporating all possible error scenarios. The probability of occurrence for each error scenario is
modeled as a weighting factor in the objective function [1]. Mini-max optimization is another method used to achieve
a treatment plan satisfying specified plan quality criteria despite all errors that may occur during fractionation. The
goal here is to find the optimal treatment plan that will guarantee a successful treatment in presence of the worst
case scenario [2]. Inclusion of the worst case scenario may result in a robust plan in terms of target coverage, but
may also result in a too high dose to the adjacent critical structures. Therefore it is desirable to be also robust in
terms of healthy tissue sparing. The motivation behind combining robust optimization with adaptive strategies is to
reduce the negative effects of uncertainties on healthy tissue close to the target during the fractionated treatment. By
using a feedback process during the fractionation schedule the uncertainties in treatment delivery can be measured
and their impact on the cumulative dose distribution can be quantified. This may allow for adaptation of the robust
optimization problem. Three different adaptive strategies are applied to and evaluated on a one-dimensional phan-
tom. The evaluations of the delivered dose are carried out according to predefined schedules. The treatment plan,
if necessary, is reoptimized for the subsequent fractions in accordance with the three adaptive strategies. Moreover,
measures are introduced to identify those patients from the simulations who will benefit the most from an adaptive
treatment approach, since previous studies have concluded that not all patients may benefit to the same extent from
an adaptive treatment [3, 4]. In the first strategy, the measured treatment errors are evaluated in order to update the
uncertainty scenarios of the systematic and random errors and their probabilities in the robust optimization problem.
The adapted plan is reoptimized with respect to the individual uncertainty distribution. In the second strategy, the
grade of conservativeness is adapted depending on the extent of the geometric errors and their impact on the delivered
dose distribution. In the third strategy, the safety margin around the clinical target volume is recalculated based on
the measured systematic and random errors giving an adapted planning target volume in the optimization problem.
By studying an idealized geometry it is possible to focus on the mathematical concepts of robust adaptive strategies.
The aim of this work is to introduce a proof-of-concept framework of an adaptive treatment planning approach.
By studying the effect of the three strategies combined with various adaptation schedules on the cumulative dose
distribution and treatment quality, in the presence of geometric uncertainties, the group benefiting the most from a
robust adaptive approach may be identified and which schedule and strategy combination may be most suitable for
this particular group of patients.
II. Geometry Model
For this study a one-dimensional phantom as depicted below in Figure 1 is considered. The model schematically
represents a slice of a two-dimensional phantom or the intersection of a sagittal and transversal cut of a three-
dimensional geometry. We consider to irradiate the target with a perpendicular oriented field. The phantom is
descretized in 101 voxels and the absorbed dose in each voxel is modeled by Gaussian functions at a spacing of 1 mm
with a standard deviation of 3 mm. Acquiring the planning CT (pCT) is the first step in the radiation treatment
planning process. Based on this image a radiation oncologist defines the tumor volume(s) which should receive a
specified amount of radiation dose and the critical structures whose dose must not exceed specified tolerance levels.
The clinical target volume (CTV) is an extension of the visible tumor in order to account for microscopic spread of
cancer cells. In order to account for external and internal movements a safety margin around the CTV is applied,
which creates the planning target volume (PTV). The organs at risk (OAR) are located asymmetrically around the
target creating a minor overlap with the PTV. We follow van Herk, et al. [5] who derived the following CTV-PTV-
margin-formula
m = 1.96Σtot + 0.7σtot (1)
3-5 5-2.5
-2.34 2.34
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PTV
FIG. 1. One-dimensional patient phantom. The dimensions are given in cm
for a one-dimensional geometry, which satisfies the ICRU criterion [6] that 99% of the CTV should receive at least
95% of prescription dose. The margin m is derived from the standard deviation of the overall systematic and random
errors, Σtot and σtot respectively.
III. Mathematical Model
In order to study the concept of adaptive radiation therapy strategies and reduce the computational effort, inter-
fractional variations are simulated by rigid shifts of the whole geometry. By doing so, the movements of each voxel and
the dose received at each fraction and in the end of the treatment can be tracked in a straightforward manner. The
proposed methods are all designed to take into account systematic and random geometric errors. The uncertainties
may originate for example from patient setup errors, organ motion or inaccuracies in dose delivery systems. It is as-
sumed that random errors differ from fraction to fraction, while the systematic error remains the same over the whole
treatment which is divided into N fractions. Therefore, the model assumes the random errors to be independent and
identically distributed over the whole course of a treatment. For the purpose of tractability, the geometric errors are
accounted for during the optimization process by discretizing their probability distributions into scenarios [2, 7]. The
set S contains all scenarios of the systematic errors with a the a priori normal distribution distribution p with a given
mean µ and standard deviation Σ. These discrete scenarios are obtained by adapting the probability distribution of
the shifts to the voxel-grid according to the mean and standard deviation. The set T contains N -tuples of the random
error scenarios which are assumed to follow the a priori normal distribution q with a given mean µq and standard
deviation σ. Every element TNn in an N -tuple represents a realized uncertainty scenario for a fraction n. In order
to reduce dose heterogeneity we introduce the set U which contains scenarios for errors following the distribution pσ
conditioned on a random standard deviation σu [2, 8].
A. Nominal Plan
The nominal plan corresponds to the procedure of adding safety margins around the CTV. The planned dose is
supposed to cover the whole PTV which ensures sufficient CTV coverage during the whole course of the treatment.
In the traditional treatment approach the same treatment plan is delivered during all fractions. The optimization
problem with the optimization function fr with r ∈ R, is formulated according to
minimize
x∈X
∑
r∈R
wrfr(d). (2)
The set R contains the regions of interest, PTV, right OAR, left OAR and external, included in the optimization
problem, where the importance weights for the corresponding regions are denoted by wr. In this objective function one
weighted sum with one set of weights is considered. There is the possibility of extending problem (2) to a multicriteria
optimization problem, which is not studied here. The set X is a collection of all feasible treatment parameters. The
dose vector d is a function of the fluence x. The form of the optimization function fr(d) is formulated as a quadratic
penalty function
fr(d) =
∑
v∈Vr
∆v,r(dv − dˆr)2, (3)
where the relative volume of voxel v in volume r is ∆v,r which satisfies
∑
v∈Vr ∆v,r = 1. The set of voxels for the
corresponding structure r ∈ R is referred to as Vr. The objective function sets a quadratic penalty for deviations of
the voxel dose dv from the prescribed voxel dose dˆr, aiming at a uniform dose distribution inside the target structure.
4B. Robust Plan
The goal of robust optimization is to create plans which take into account random and systematic errors simulta-
neously. In contrast to the nominal plan where the PTV is considered to be the high dose target, the focus here lies
on optimizing the uniform dose in the CTV in presence of geometric errors. This approach may result in a robust
fluence profile similar to applying CTV-PTV-margins. Conditional-value-at-risk (CVaR) optimization [9] enables to
continuously scale between probabilistic and worst case scenario optimization. This is realized by maximizing over
the worst systematic error scenarios after a stochastic minimax optimization with respect to the α worst random
standard deviations for the expected random errors has been performed. The following problem formulation has been
proven to be effective by Fredriksson [2],
minimize
x∈X
max
0≤pi≤ 1αp
eTpi=1
Epi
[
max
0≤ρ≤ 1αpσ
eT ρ=1
Eρ
[
Eq(σU)[(f(d(x,S,U , T ))]
]]
. (4)
Besides the fluence x, the other two variables in the above stated optimization problem ( 4) are the probabilities of
the systematic error scenarios p and pσ of the unknown random error scenarios, denoted by pi and ρ respectively.
The closer α is to 1, the less conservative the radiation plan will be. Thus for α = 1, the resulting optimization
problem (4) corresponds to probabilistic optimization [2]. On the other hand, lowering α to αs ≤ mins∈S ps with
ps > 0 is equivalent to worst case optimization. The problem (4) can be written as one minimization problem taking
the dual of its inner maximization problem, thus providing continuous derivatives to the optimization solver. For
every systematic error s ∈ S additional auxiliary variables λ¯(s) and µ¯(s) are necessary. The variable λ¯(s) is a scalar
for the CVaR optimization over the α worst systematic error scenarios, while µ¯(s) is a vector of length |U|. The
optimization problem takes the form
minimize
x,λ,µ,λ¯,µ¯
λ+
1
α
pTµ
subject to λ+ µs ≥ λ¯(s) + 1
α
pTσ µ¯(s), s ∈ S,
λ¯(s) + µ¯u(s) ≥ Eq(σu)[f(d(x, s, u, T ))], s ∈ S, u ∈ U ,
µ¯(s) ≥ 0, s ∈ S, µ ≥ 0, x ∈ X .
(5)
IV. Adaptive Strategies
The method described in section III B is based on anticipated scenarios conditioned on an a priori probability
distribution. The optimal solution to (5) provides a fluence profile x ∈ X which is robust against the included
uncertainties. This robust plan is delivered in the first M − 1 fractions. Rigid whole-body movement can be modeled
as isocenter shifts for a one-dimensional patient geometry. These isocenter shifts ∆r1, ∆r2, ...,∆rM−1 are measured
during the first M − 1 fractions. The impact of these treatment errors on the dose distribution is assumed to be
analyzed after fraction M − 1. In case of non-negligible deviations from the planned dose distribution, adaptive
replanning based on the actual measured errors has to be considered. The adapted fluence profile, also referred to as
plan, is then applied in fractionM and the subsequent fractions until another adaptation may be necessary. Therefore,
adapted plans may provide sufficient target coverage while giving little dose to the adjacent healthy tissue for the rest
of the treatment.
A. Strategy I: Adaptation of the Probability Distribution
In the first strategy, the uncertainty sets S and T are adapted based on the measured isocenter shifts ∆r1,∆r2, . . . ,
∆rM−1. These updated uncertainty sets replace the previous uncertainty sets in the robust optimization problem (5).
After having modified (5), the solver generates an adapted plan. The distribution of the isocenter shifts can be
adapted in different ways according to the measurements ∆r0,∆r1, ∆r2, . . . ,∆rM−1 , where ∆r0 denotes the patient
position in the planning CT.
Uncertainty Set Adaptation based on Arithmetic Mean Value: The first approach is based on the arith-
metic mean value. According to Unkelbach and Oelfke [1] the isocenter position ∆iM which is the basis
for the updated probability distribution of the systematic error may be determined by the mean value of
5the measured patient position ∆iM = 1M
∑M−1
µ=0 ∆rµ. The updated standard deviation σiM is estimated
by σi2M =
1
M
∑M−1
µ=0 (∆rµ − ∆iM )2. Since the uncertainty set for the systematic errors is based on the nor-
mal distribution, the mean value µ and standard deviation Σ used in the planning stage are replaced by ∆iM
and σiM . The adapted uncertainty scenarios for the systematic errors s′ ∈ S ′, the adapted uncertainty set,
and their assigned probabilities p′ are obtained from discretizing the normal distribution N (∆iM , σi2M ) with
respect to the voxel grid. This discretization process of the adapted normal distribution is done in the same
way as for the a priori distribution N (µ,Σ2). The uncertainty set S in (5) is then replaced by S ′. In this
work, the adaptive model is extended to include the random errors as well. The adaptation of the random
error scenarios is modeled similarly to that of the systematic errors. First, the distances of the measured
points∆r1,∆r2, ...,∆rM−1 relative to the updated mean value ∆iM of the systematic error distribution are
determined. The updated mean value ∆jM and standard deviation σjM of the random error distribution is
obtained from ∆jM = 1M
∑M−1
µ=0 (|∆rµ −∆iM |) and σj2M = 1M
∑M−1
µ=0 (∆rµ −∆jM )2.
Uncertainty Set Adaptation based on Exponential Smoothing: The second approach is based on exponen-
tial smoothing and is inspired by Chan and Mišić [10] who used this method to compute the updated
mean value ∆iM . Let rˆµ+1 denote the forecast of the mean value of the systematic errors for the upcom-
ing fractions M,M + 1, . . . N . The forecast is obtained from a convex combination of the so far measured
shifts ∆rµ, where µ = 0, 1, . . . ,M − 1. The weights of the past measurements decay exponentially as the
observations get older.
rˆµ+1 = β∆rµ + (1− β)rˆµ, 0 ≤ β ≤ 1. (6)
The advantage of using an update scheme as proposed in (6) is the possibility to vary the speed of adaptation
by assigning higher or lower values to the smoothing parameter β. The arithmetic mean on the other hand
assigns the same weight to all measurements, which gives a convex combination of the previously computed
mean value ∆iM−1 and the most recent measurement ∆rM−1 multiplied by 1M−1 . In order to determine the
standard deviation σµ+1 for the exponential smoothing method, it is recommended to use the mean absolute
value deviation (MAD) and the formula σ ≈ (1.25)MAD [11, chapter 4]. The estimate of MAD for fraction µ
is denoted by MADµ. MAD is the average deviation of each measurement ∆rµ from the mean rˆµ. The forecast
for MAD in fraction µ+ 1 is computed by exponential smoothing with the smoothing parameter β
MADµ+1 = β|∆rµ − rˆµ|+ (1− β)MADµ, σˆµ+1 ≈ (1.25)MADµ+1. (7)
We setM = µ+1, since we are interested in the forecast for the upcoming fractionM . The updated uncertainty
set S ′ contains scenarios based on the probability distribution N (rˆM , σˆM ) which is part of the basis for the
adapted plan to be delivered in fraction M . The next step is to determine the updated set of random errors T ′
using the exponential smoothing method, which is an extension of previous models. Let δµ = |∆rµ − rˆM |
denote the deviation of the measurements ∆r0,∆r1,∆r2, ...,∆rM−1 from the recently obtained mean rˆM . The
computation of the mean random error during the first M − 1 fractions is carried out according to δˆµ+1 =
βδµ + (1 − β)δˆµ with 0 ≤ β ≤ 1. The standard deviation of the random error ρˆM = ρˆµ+1 is computed in the
same manner as for the systematic error. The random error scenarios are then based on the discretized normal
distribution N (δˆM , ρˆM ), which are contained in the updated set T ′.
The fact that the adapted problem is a new optimization problem is reflected in the notation of the parameters and
the objective function. The optimization parameters p and d and the sets S and T in (5) are then replaced by p′, d′,
and the sets S ′ and T ′. The solution of this modified robust optimization problem with respect to the adapted
uncertainty sets represents the adapted plan to be delivered in fraction M and the remaining N −M + 1 fractions or
until the next adaptation is necessary.
B. Strategy II: Adaptation of CVaR parameter
The robustness of the solution of the optimization problem (5) depends on the anticipated uncertainty sets S and T .
The grade of conservativeness is determined by the value that is set for α in the robust problem (5). The aim of this
strategy is to examine how different values of α, i.e.: different levels of conservativeness, are related to the magnitude
of systematic and random errors, and how they affect the cumulative dose distribution. In case of underdosage of
the CTV, i.e. large geometric uncertainties, α is going to be decreased in order to improve robustness. In the event
of overdosage of a critical structures, α is going to be increased, since a more robust plan may not be necessary to
guarantee sufficient CTV coverage in such a scenario. The modified parameter α′ replaces α in the objective function
6organ relative volume in % relative dose in %
CTV 99 90
left OAR 20 2
right OAR 30 2
TABLE I. Dose-volume points for three structures. The dose levels are defined relative to the prescription dose.
and constraint in the original optimization problem (5). The solution of this adapted robust problem is an adapted
fluence profile to be applied in fraction M and the subsequent N −M + 1 fractions or until the next adaptation is
necessary.
C. Strategy III: Margin Adaptation
In the third and last strategy the CTV-PTV-margin is adapted according to the margin formula (1). The overall
distribution of the adapted systematic and random error, Σ′tot and σ′tot respectively, are based on the obtained
measurements {∆r0,∆r1,∆r2, ...,∆rM−1}. The adapted standard deviations Σ′tot and random error σ′tot are computed
from the arithmetic mean value or by exponential smoothing, as in (7). The updated margin m is used to define a
new PTV which is the target volume in the objective function of the nominal optimization problem (2). This adapted
problem is then solved for an updated set of voxels V ′r and relative volumes ∆v′,r for r = PTV resulting in an adapted
plan for fraction M and the remaining fractions until the next adaptation becomes necessary.
V. Computational Study
The computational study is performed in MATLAB version 8.3 using IBM’s optimization solver CPLEX in the
studio version 12.6.3, where IMRT is applied to the one-dimensional phantom geometry.
It is assumed that each patient is subjected to one individual systematic error throughout the whole treatment,
whereas the random error varies from fraction to fraction. The adaptive strategies and schedules are put to the test
by two different patient populations, containing either unpredictably large geometric errors, referred to as large error
population, or errors with a similar order of magnitude as those accounted for by the initial robust treatment plan.
The latter is referred to as small error population. In case of the small error population, the systematic error is
modelled according to the normal distribution around the mean 0 with the standard deviation of 2.5 mm, whereas
the random error is distributed around the mean 0 with standard deviation of 6.5 mm. The second population, called
the large error population, follows a random unknown distribution. The mean of the systematic and random error
is assumed to be uniformly distributed U [−3, 3]. The standard deviation of the systematic error is 3.5 mm and 7.5
mm for the random error. It should be pointed out that the simulated treatments intentionally follow distributions
different from the a priori distribution. Simulations show that adaptations are hardly required, if the treatment errors
are to similar to the a prioi errors. However, one cannot assume that the initial robust plan will be able to handle
all types of treatment errors. Therefore, the three proposed strategies are applied to both treatment populations in
order to simulate challenging patient cases, which may likely require plan adaptations. Each of these populations
contains 1000 treatments/patients, where the total dose is distributed over 30 fractions for each treatment/patient.
At a scheduled evaluation, the so far delivered dose and the dose statistics in the target and critical structures are
analyzed. If the measured dose statistics do not satisfy the predefined quality criteria, as listed in Table I, the initial
plan is adapted. These dose-volume points are recommended by ICRU (International commission on radiation units
and measurements) and RTOG (radiation therapy oncology group). This prescription is intended for a prostate cancer
case with the prescribed target dose of 70 cGy in presence of the bladder and rectum as critical structures.
In addition, the impact of adaptation frequency on the adapted plans and cumulative dose distribution is studied
by combining the three adaptive strategies with various evaluation schedules. The schedules on trial vary in the total
number of evaluations and when the evaluation takes place. They are denoted by WiEvalj, where i indicates after how
many weeks the first evaluation is carried out, whereas the total number of evaluations is given by j. The search for
the right time to evaluate the so far delivered dose and to adapt for the first time during the treatment, is addressed
by the schedules W1Eval4, W2Eval4, W1Eval3, W2Eval3, W1Eval1 and W2Eval1. The first evaluation is intended
after the first and second week of the treatment for the above mentioned schedules. The time interval between each
evaluation is one week, with the exception of two weeks between the first and second evaluation for the schedules
W1Eval4 and W1Eval3. Moreover, by studying the results of the schedules W3Eval1, W4Eval1 and W5Eval1 it is
expected to estimate after which fraction it is too late to correct for undesired overdosage in the critical structures
7and underdosage of the CTV. The schedule called Gold, refers to the approach of evaluating the to be delivered dose
before every fraction followed by a plan adaptation if necessary.
Strategy I: The robust fluence profile, also referred to as plan, is obtained from solving (5) for the parameter
α = 0.1. This plan has a high level of robustness and is applied during the first fractions, as there is no or
limited knowledge of the patient’s individual geometric uncertainty distribution. In general, the main objective
is to damage the tumor and therefore sufficient target coverage has the highest priority. If the the extent of
geometric variations is underestimated, the loss of sufficient target coverage is difficult to compensate for in later
fractions [1]. If an adaptation is necessary, an updated mean value and standard deviation are computed from the
measured errors. The exponential smoothing method is used for a set of three different smoothing parameters
β = {0.1, 0.4, 0.9}. Stronger emphasis is put on the most recent information by using a large smoothing
parameter, which can be understood as a higher adaptation speed. On the other hand, when multiplying the
most recent measurement with a smaller smoothing parameter, the speed of adaptation is lower. Therefore,
finding the smoothing parameter best suited to predict the actual individual error distribution is of interest.
Strategy II: The goal here is to determine the appropriate degree of robustness for an adaptive treatment approach.
Therefore, the treatments are simulated for initial plans with various degrees of robustness, i.e.: α is either 0.1,
0.4 or 0.9. If the OAR criteria is violated, α will be increased by 0.09. In case of underdosage of the CTV, the
value of the parameter α will decrease by 0.09. This gradual change in α is carried out in order to develop some
proper understanding how different values of α relate to the varying size of geometric uncertainties.
Strategy III: In this strategy, the nominal plan is applied until the first scheduled evaluation. If one of the predefined
quality criteria is not met, an adapted CTV-PTV-margin is used to compute a reoptimized plan according to (2)
and (3). In contrast to this strategy, the previously described strategies are considered less conservative.
VI. Results
A. Non-Adaptive Strategies
Non-adaptive strategies refer to the traditional approach of using the same plan in all fractions of the treatment.
This treatment strategy is intended as a benchmark for further comparison with the adaptive strategies and their
potential to improve the overall treatment outcome.
The nominal and robust plan are applied to the small error and large error population and evaluated in terms
of target coverage and OAR protection, which is illustrated in Table II. The success rate refers to percentage of
patients who receive a treatment with a cumulative dose distribution that satisfies all three predefined plan quality
criteria. The terms lowest D99 for the CTV, and highest D30 and D20 for both OARs describe the worst possible
outcome of the predefined quality criteria. According to the simulations with both populations, higher success rate
and much lower dose to the critical structures is achieved by the robust plan. The dose received by the OARs in the
worst possible outcomes for both plans is lower in the large error population than in the small error population. This
difference is caused by the wider spread of the geometric errors which smear out the cumulative dose distribution to
a greater extent than the errors in the small error population. The outstanding performance of the robust-optimized
plan applied to small error distribution with a success rate of 98% suggests that adaptation may be only necessary
in some exceptional cases, as the a priori uncertainty distribution is similar to the simulated treatment uncertainty
distribution. A treatment with the nominal plan achieves a lower success rate of 59% because of too high doses received
by the OARs. This difference is not surprising as the robust plan is optimized with respect to the target and the
OARs, while it is the nominal plan’s main objective to secure target coverage. On the contrary, the simulations with
the large error population give lower success rates of 2% and 32% of the nominal and robust plan, respectively. Thus,
combining robust treatment planning with adaptive strategies may increase the probability to satisfy the predefined
quality criteria.
B. Adaptive Strategies
The number of patients who require an adapted plan at each evaluation is one of the investigated measures. The
ratio of these type of patients is referred to as ART candidates and measured in %.
Strategy I: This strategy is applied to both patient populations in order to review the different adaptation schedules
in combination with adaptation methods which are based on either arithmetic mean or exponential smoothing.
8Strategy success rate in % lowest D99 CTV highest D30 right OAR highest D20 left OAR
(failed patients) in % (failed patients) in % (failed patients) in %
small error population
Nominal Plan 59 98 (0) 41 (9) 82 (14)
Robust Plan 98 82 (2) 4 (0.4) 16 (0.7)
large error population
Nominal Plan 2 97 (0) 22 (69) 35 (82)
Robust Plan 32 84 (64) 8 (16) 9 (18)
TABLE II. Performance overview of the treatment strategies without any adaptation under trial for the simulated small and
large error patient population. The worst possible outcome in terms of target coverage and organ at risk protection and the
percentage of patients failing the specific goal are listed.
The potential of the adaptive strategy I to improve OAR protection, compared to non-adaptive strategies in
presence of unpredictably large variations is similar for the schedules W1Eval4 and W2Eval4. The values
of the worst possible outcomes for schedule W1Eval4 are illustrated in Table III, where the numbers in the
parentheses refer to the percentage of patients who fail at the specific goal. Since the right OAR is located
closer to the CTV than the left OAR, meeting the predefined quality criterion for the right OAR is challenging.
Thus, a higher percentage of patients do not pass this particular quality criterion compared to the number
failing the criterion for the left OAR. In general, the quality criteria seem to be satisfied depending on the
adaptation method. The highest percentage of succeeding patients for the CTV quality criterion is reached
by the exponential smoothing method with β = 0.1. Furthermore, the heuristic analysis indicates a potential
for improved risk organ protection and target coverage, as the overall success rate can be increased to 66%
compared to 32% after a non-adaptive treatment with the robust plan, as shown in Table IV. The non-adaptive
strategy with the nominal plan gives a success rate of only 2%. Concerning the speed of adaptation, the
simulations may indicate that the adaptation methods with a higher weight on more recent measurements
have difficulties in satisfying the predefined quality criteria at the scheduled evaluation fractions. The results
in Table IV suggest that strategy I in combination with exponential smoothing does adapt quite accordingly
to the simulated uncertainty distribution for a majority of simulated patients. By setting a higher weight on
earlier measurements, i.e.: a smoothing parameter β = 0.1, 0.4, the predictions of future uncertainties may be
more accurate than by taking the mean of all measurements [11, chapter 4]. The performance of strategy I in
presence of errors from the large error distribution can be also investigated through dose-probability histograms,
as illustrated in Figure 2. The histograms in Figure 2(a) and 2(b) give information on the probability that the
cumulative dose distribution satisfies the predefined quality criteria for the different adaptation methods. The
probability, plotted on the y-axis, that 99% of the CTV will receive at least a certain dose level or above, plotted
on the x-axis, is the highest for the exponential smoothing method with β = 0.1, as shown in Figure 2(a). The
probability for achieving the same dose levels is slightly lower for the smoothing parameter β = 0.4, whereas
the other two methods reach a much lower probability. On the other hand, setting a greater emphasis on the
most recent measurement, as done by setting β = 0.9, seems to be most favourable for satisfying the quality
criterion for the right OAR, as illustrated in Figure 2(b). The probability to reach the same dose levels by 30%
of the right OAR is lower for β = 0.1 and 0.4. Again, the adaptation method based on the arithmetic mean
achieves the lowest probability to fulfil this particular clinical goal. According to the simulations, the adaptation
speed has a measurable impact on the probability for sufficient target coverage and OAR protection. A lower
adaptation speed, i.e.: β = 0.1 or 0.4, may lead to a higher probability of target coverage and acceptable OAR
protection at the same time. Furthermore, the simulations for the remaining schedules suggest that adaptation
is most beneficial, if carried out during the first half of the treatment, as deviations from the intended dose
distribution seem to be more difficult to be compensated by later adaptations. However, applying the same
schedules and strategy to the small error population suggests that neither the adaptation schedule nor the speed
of adaptation significantly affect the final success rate or target coverage. The success rate is comparable to
the non-adaptive approach as the robust plan accounts for treatment errors similar to those in the small error
population, the success rate of the robust non-adaptive approach is comparable to that of strategy I, independent
of the adaptation schedule. Therefore, it can be concluded that not all patients may necessarily have greater
benefits from an adaptive approach, if their interfractional motion pattern has been accurately anticipated by
the initial robust plan.
Additional simulations with a subset of 100 cases of the large error population are performed in order to
investigate up to which extent the cumulative dose distribution can be improved, if adaptations can be triggered
9lowest D99 CTV highest D30 right OAR highest D20 left OAR
(failed patients) in % (failed patients) in % (failed patients) in %
arithmetic mean 76 (41) 54 (65) 26 (40)
exp. smoothing β = 0.1 88 (3) 35 (58) 17 (33)
exp. smoothing β = 0.4 79 (13) 40 (51) 19 (29)
exp. smoothing β = 0.9 60 (70) 12 (18) 8 (16)
TABLE III. Comparison of the performance of four different updating procedures for the schedule W1Eval4 with strategy I
subjected to treatment scenarios from the large error population. The worst possible outcome in terms of target coverage and
organ at risk protection are illustrated and the percentage of patients failing the specific goal are listed in parentheses.
at each fraction. This evaluation schedule under trial is referred to as the Gold schedule. The set of simulated
treatments is kept small because of long computation times. The simulations with the large error population
suggest that in presence of unpredictably large geometric uncertainties a higher adaptation frequency may not
necessarily lead to an improved success rate, which is illustrated by Table V. This could be caused by the high
evaluation and adaptation frequency adding noise to the sample of geometric uncertainty measurements. As
these measurements build the basis for the reoptimization process, the adapted plans may not be in accordance
with the actual uncertainty distribution.
Strategy II: Here, the grade of conservativeness is adjusted in response to unsatisfied predefined dose-volume points.
Strategy II is applied to both patient populations in order to understand how robust the initial plan has to be in
presence of large or small geometric uncertainties. The simulations indicate that the grade of conservativeness
can be lower, i.e.: higher α, for a treatment that is designed in an adaptive manner, as the highest success rate
is achieved for the value α = 0.9 accompanied by a high adaptation rate, for both populations. Throughout
the simulated treatments a trend for a decreasing α is observed as the treatment progresses, suggesting that
adaptation is triggered by insufficient target coverage. Moreover, it may be concluded that the adjustment of
a single parameter may not be sufficient to compensate for previously missed plan-quality criteria, especially in
the event of unpredictably large geometric errors from the large error population. In case of these larger errors,
it is observed that the reoptimized plans tend to underdose the CTV, as the protection of the critical structures
might be in conflict with the objective for sufficient target coverage.
Strategy III: The simulations with the large error population suggest that the use of CTV-PTV-margins leads to
overdosage of the critical structures while ensuring sufficient target coverage. This result is not surprising since
target coverage is prioritized in the conventional planning procedure. Due to the broader error distribution
the adapted margins increase after the first adaptation and as the treatment progresses. In accordance with
previous simulations an adaptive treatment design may not require a conservative initial plan. According
to the simulations with the large error population, strategy III achieves quite low success rates compared to
the previously studied strategies. An increased speed of adaptation, i.e.: large smoothing parameter β =
0.9, improves the overall success rate from 2%, in the non-adaptive strategy with the nominal plan, to 21%.
Adaptation of the nominal plan decreases the cumulative dose in the risk organs. Still, the CTV-PTV-margins
applied during the treatments may become quite large for patient cases with large geometric variations, as target
coverage throughout the treatment is prioritized. Together with the preceding simulations, it may be concluded
that a less conservative plan, i.e.: smaller margins, is better suited for an adaptive treatment approach which
aims at targeting the CTV and protecting the OARs at the same time. On the other hand, simulations with
the small error population indicate that strategy III yields adaptation rates similar to those of the previously
tested strategies.
VII. Discussion
As the scope of this work is to establish a proof-of-concept adaptive framework, non-rigid variations such as tumor
deformations are neglected in order to simplify the calculations. Thus, setup and delineation errors are modeled
as rigid shifts [2, 5, 12]. This study is carried out on basis of the results of the heuristic simulations. Due to the
simplified treatment- and patient model, the presented numbers for adaptation rates, schedules and strategies should
be interpreted and compared in relative terms. The simulations are supposed to give trends how the adaptation
of various parameters affect and possibly improve the success rate in the presence of geometric errors. Conclusions
are drawn from the treatment simulations with the large and small error population. Thus, all discussed adaptive
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ART candidates in % success rate in %
Schedule W1Eval4
fraction number 5 15 20 25 ∩{5,15,20,25} 30
arithmetic mean 32 60 67 75 32 44
exp. smoothing β = 0.1 32 55 58 70 26 66
exp. smoothing β = 0.4 32 57 60 66 28 64
exp. smoothing β = 0.9 32 57 64 71 29 29
Schedule W2Eval4
fraction number 10 15 20 25 ∩{10,15,20,25} 30
arithmetic mean 32 58 67 74 22 45
exp. smoothing β = 0.1 32 54 58 66 26 65
exp. smoothing β = 0.4 32 57 60 66 27 63
exp. smoothing β = 0.9 32 58 65 73 30 28
TABLE IV. Comparison of the performance of four different updating procedures for the schedules W1Eval4 and W2Eval4
with strategy I after simulations with the large error population. The percentage of patients whose cumulative dose distribution
satisfy the D99, D20 and D30 dose-volume criteria throughout the treatment can be compared for the two schedules.
(a)Dose-Probability histogram comparing the probability that
99% of the CTV will receive a certain minimum dose or
higher.
(b)Dose-Probability histogram comparing the probability that
30% of the right OAR will receive a certain maximum dose or
lower.
FIG. 2. The figure compares four different adaptation speeds for strategy I with the schedule W1Eval4, after simulations with
the large error population.
and non-adaptive strategies are compared with respect to the same treatment uncertainties and plan quality criteria,
which results in a fair comparison of the cumulative dose distributions. In this study, bootstrap resampling is used to
asses the statistical accuracy and predictive value of the simulated treatment scenarios. This method is based on the
basic idea to randomly draw datasets with replacement from an original dataset. By doing this k times, a number
of k bootstrap datasets are created, where each sample has the same size as the original dataset. Resampling is a
helpful tool, whenever studies are subjected to a limited number of patient cases [13, 14]. The largest impact on the
dose distribution is caused by the largest geometric errors. Therefore, the resampling procedure is carried out with
the largest errors over the whole treatment of each patient. This procedure is executed over the whole population
where 500 datasets are created and the probability density estimate for the standard deviation of the worst case error
over the whole large error patient population is computed. As a result, a narrow spread of the standard error is
determined, which indicates that the used data set is large enough for quantitative conclusions on the very different
performances of the three adaptive strategies. The simulated treatment scenarios and patient geometry turned out to
be quite challenging for the robust adaptive strategies to satisfy the predefined quality criteria, as intended from the
beginning of the study. Still, it was possible to identify which model parameters and strategy perform well in these
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most common success rate lowest D99 CTV highest D30 right OAR highest D20 left OAR
number of adaptations in % (failed patients) in % (failed patients) in % (failed patients) in %
19 49 87 (31) 20 (84) 7 (38)
TABLE V. Summary of adaptation frequency, -rate, success rate and worst possible outcomes after simulated treatments of
100 patients from the large error population according to the Gold schedule. The percentage of patients failing the specific
goal is listed in parentheses. The adaptation is performed according to the exponential smoothing method with smoothing
parameter β = 0.1.
challenging treatment scenarios. Therefore, the simulations may represent a guide for further development of robust
adaptive treatment strategies.
VIII. Conclusion
A framework is presented that provides robust optimized and margin adaptation of the treatment plan throughout
the fractioned schedule. Measures are introduced which identify patients in need for an adaptive treatment strategy.
According to the simulations the combination of evaluation and adaptation schedules with robust reoptimization with
respect to predefined plan quality measures may be a useful framework for patient identification. Such treatment
strategies open the opportunity to provide individualized plans. Smaller geometric variations are less sensitive to
the choice of adaptation strategy as similar geometric variations are already taken into account by the initial robust
plan. Still, the dose to the critical structures can be decreased if any of the three strategies is employed. The
impact of geometric variations on the dose distribution could be detected and candidates for an adaptive treatment
identified. The lower adaptation rate in the small error population is in line with previous studies [3, 4] which stated
that not all patients may benefit from an adaptive approach in the same extent. The higher adaptation rate for
the large error population, i.e.: higher number of adaptation candidates, is caused by its larger errors than those
included in the a priori distribution. However, these simulations show that the cumulative dose distribution can be
corrected for a majority of simulated patient treatments. Strategy I seems to achieve the highest success rate and
probability for sufficient target coverage and organ at risk protection. Most promising improvements are made when
the adaptations are carried out on a weekly basis with the first adaptation done during the first half of the treatment.
Thus, the simulations imply that combining robust treatment planning with adapting the uncertainty scenarios and
their assigned probabilities lead to measurable improvements of treatment quality in comparison to conventional
non-adaptive strategies. This study is considered to provide a useful base for further development towards more
complicated geometries and an optimization model utilizing finite horizon optimal control.
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